Market Cap (In USD)
17.38 Million
Revenue (In USD)
-
Net Income (In USD)
-11.98 Million
Avg. Volume
5.73 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.51-5.01
- PE
- -
- EPS
- -
- Beta Value
- 6.726064
- ISIN
- US60458C1045
- CUSIP
- 60458C104
- CIK
- 1904286
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Mr. Erez Aminov
- Employee Count
- -
- Website
- https://mirapharmaceuticals.com
- Ipo Date
- 2023-08-14
- Details
- MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
More Stocks
-
300234
-
ETP
-
CLDT-PAChatham Lodging Trust
CLDT-PA
-
QUANTDIA
-
PEGX
-
SPACEINCUBASpace Incubatrics Technologies
SPACEINCUBA
-
AMMN
-
MFC